Cargando…

Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment

BACKGROUND: The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL/METHODS: Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolny-Rokicka, Edyta I., Wydmański, Jerzy, Tukiendorf, Andrzej, Mróz, Piotr, Zembroń-Łacny, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278351/
https://www.ncbi.nlm.nih.gov/pubmed/30479323
http://dx.doi.org/10.12659/MSM.910280
_version_ 1783378345641115648
author Wolny-Rokicka, Edyta I.
Wydmański, Jerzy
Tukiendorf, Andrzej
Mróz, Piotr
Zembroń-Łacny, Agnieszka
author_facet Wolny-Rokicka, Edyta I.
Wydmański, Jerzy
Tukiendorf, Andrzej
Mróz, Piotr
Zembroń-Łacny, Agnieszka
author_sort Wolny-Rokicka, Edyta I.
collection PubMed
description BACKGROUND: The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL/METHODS: Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had undergone radiotherapy were prospectively reviewed between January 2014 and December 2016. The study investigated the relationship between the biochemical results, the disease stage, and the survival rate in lung cancer patients. Post-treatment coagulation-based D-dimer (DD), fibrinogen (Fib), and complete blood count (CBC) were evaluated during the follow-up over a period of 2 years after treatment or until the patient’s death. RESULTS: An increase of D-dimer generates an increased chance of early death by approximately 0.03% per 1 D-dimer unit. In cases when the difference in the D-dimer concentration equals 1000, the risk of an early death increases by (1.00031000−1)×100%=35%. CONCLUSIONS: High levels of D-dimer are associated with an advanced form of disease with metastasis and higher risk of early death in lung cancer patients.
format Online
Article
Text
id pubmed-6278351
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-62783512018-12-27 Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment Wolny-Rokicka, Edyta I. Wydmański, Jerzy Tukiendorf, Andrzej Mróz, Piotr Zembroń-Łacny, Agnieszka Med Sci Monit Clinical Research BACKGROUND: The aim of this paper was to investigate the association between clinicopathological factors and the coagulation test in lung cancer patients during follow-up care after treatment. MATERIAL/METHODS: Ninety-five medical patients with histologically proven advanced lung carcinoma (LC) who had undergone radiotherapy were prospectively reviewed between January 2014 and December 2016. The study investigated the relationship between the biochemical results, the disease stage, and the survival rate in lung cancer patients. Post-treatment coagulation-based D-dimer (DD), fibrinogen (Fib), and complete blood count (CBC) were evaluated during the follow-up over a period of 2 years after treatment or until the patient’s death. RESULTS: An increase of D-dimer generates an increased chance of early death by approximately 0.03% per 1 D-dimer unit. In cases when the difference in the D-dimer concentration equals 1000, the risk of an early death increases by (1.00031000−1)×100%=35%. CONCLUSIONS: High levels of D-dimer are associated with an advanced form of disease with metastasis and higher risk of early death in lung cancer patients. International Scientific Literature, Inc. 2018-11-27 /pmc/articles/PMC6278351/ /pubmed/30479323 http://dx.doi.org/10.12659/MSM.910280 Text en © Med Sci Monit, 2018 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Wolny-Rokicka, Edyta I.
Wydmański, Jerzy
Tukiendorf, Andrzej
Mróz, Piotr
Zembroń-Łacny, Agnieszka
Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
title Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
title_full Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
title_fullStr Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
title_full_unstemmed Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
title_short Appraisal of Basic-Hemostatic Markers in Lung Cancer Patients During Follow-Up Care After Radiotherapy Treatment
title_sort appraisal of basic-hemostatic markers in lung cancer patients during follow-up care after radiotherapy treatment
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278351/
https://www.ncbi.nlm.nih.gov/pubmed/30479323
http://dx.doi.org/10.12659/MSM.910280
work_keys_str_mv AT wolnyrokickaedytai appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment
AT wydmanskijerzy appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment
AT tukiendorfandrzej appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment
AT mrozpiotr appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment
AT zembronłacnyagnieszka appraisalofbasichemostaticmarkersinlungcancerpatientsduringfollowupcareafterradiotherapytreatment